Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous RAK cells
- Development stage
- Unknown
- Lead developer
- 普华赛尔
- Modality
- Cell Therapies
- Administration
- Intravenous
01
Overview
Autologous RAK cells are a cell-based immunotherapy consisting of a patient's own immune cells, primarily CD8+ T cells and natural killer T (NKT) cells, which are expanded ex vivo and administered via intravenous infusion. Developed by Puhua Saier Biomedical Technology in collaboration with TaKaRa Biomedical Technology, this adoptive cellular immunotherapy leverages the cytotoxic activity of these expanded cells to target and eliminate tumor cells. It is currently being investigated for the treatment of advanced clear cell renal cell carcinoma (ccRCC) and hepatocellular carcinoma (HCC), particularly in patients who have failed prior systemic therapies such as immune checkpoint inhibitors and VEGF tyrosine kinase inhibitors.
- Other names
- autologous RAK cell injectionautologous RAK cell infusion
02
Targets
VCAM-1 (Vascular cell adhesion protein 1)MICB (Major histocompatibility complex class i-related protein B)NECTIN1 (Poliovirus receptor-related 1)pMHC (Peptide-MHC complex family)
Beyond the preview
Go deeper on autologous RAK cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous RAK cells.